Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers.

[1]  Jean Mosser,et al.  Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) , 2016, The Lancet.

[2]  A. Meert,et al.  Inequalities in lung cancer: a world of EGFR , 2016, European Respiratory Journal.

[3]  M. Krasnik,et al.  The prevalence of EGFR mutations in non‐small cell lung cancer in an unselected Caucasian population , 2015, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[4]  M. Ladanyi,et al.  Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium , 2015, Cancer.

[5]  M. Salido,et al.  Assessment of ALK Status by FISH on 1000 Spanish Non-Small Cell Lung Cancer Patients , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  D. Ettinger,et al.  Molecular alterations in non-small cell lung carcinomas of the young. , 2014, Human pathology.

[7]  Y. Sohara,et al.  Genes associated with succeptibility to lung adenocarcinoma among never smokers suggest the mechanism of disease. , 2014, Anticancer research.

[8]  Chan Kwon Park,et al.  Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non‐small‐cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage , 2014, Journal of surgical oncology.

[9]  L. Crinò,et al.  Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcome in Resected Non–Small Cell Lung Cancer Patients , 2014, American journal of clinical oncology.

[10]  X. Lv,et al.  Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer , 2014, Journal of Cancer Research and Clinical Oncology.

[11]  B. Ghanim,et al.  Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy. , 2014, European journal of cancer.

[12]  H. Baloglu,et al.  EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study , 2014, Medical Oncology.

[13]  S. Knuutila,et al.  Epidermal Growth Factor Receptor Mutations in 510 Finnish Non–Small-Cell Lung Cancer Patients , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  T. Nakajima,et al.  Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: A prospective, single‐institute study , 2014, Cancer.

[15]  M. Antoine,et al.  Prospective screening for ALK: clinical features and outcome according to ALK status. , 2014, European journal of cancer.

[16]  P. Russell,et al.  The Clinical Relevance of Pathologic Subtypes in Metastatic Lung Adenocarcinoma , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  V. Nandakumar,et al.  Frequent Mutations in EGFR, KRAS and TP53 Genes in Human Lung Cancer Tumors Detected by Ion Torrent DNA Sequencing , 2014, PloS one.

[18]  C. Huang,et al.  Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts , 2014, British Journal of Cancer.

[19]  J. V. van Meerbeeck,et al.  Routine implementation of EGFR mutation testing in clinical practice in Flanders: ‘HERMES’ project , 2014, Acta clinica Belgica.

[20]  M. Perelman,et al.  Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens. , 2014, Clinical lung cancer.

[21]  E. Nexo,et al.  EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer. , 2014, Lung cancer.

[22]  F. Tanaka,et al.  Frequency of epidermal growth factor receptor mutations in Bangladeshi patients with adenocarcinoma of the lung , 2014, International Journal of Clinical Oncology.

[23]  S. Thongprasert,et al.  A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  Quan Zhang,et al.  Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status , 2014, Journal of Cancer Research and Clinical Oncology.

[25]  D. Lin,et al.  The Molecular Detection and Clinical Significance of ALK Rearrangement in Selected Advanced Non-Small Cell Lung Cancer: ALK Expression Provides Insights into ALK Targeted Therapy , 2014, PloS one.

[26]  U. Müller-Lisse,et al.  Preselection Based on Clinical Characteristics in German Non–Small-Cell Lung Cancer Patients Screened for EML4-ALK Translocation , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  Tao Jiang,et al.  EGFR Mutations in Surgically Resected Fresh Specimens from 697 Consecutive Chinese Patients with Non-Small Cell Lung Cancer and Their Relationships with Clinical Features , 2013, International journal of molecular sciences.

[28]  R. McCormack,et al.  First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study , 2013, British Journal of Cancer.

[29]  Quan Zhang,et al.  Comparison of EGFR signaling pathway somatic DNA mutations derived from peripheral blood and corresponding tumor tissue of patients with advanced non-small-cell lung cancer using liquidchip technology. , 2013, The Journal of molecular diagnostics : JMD.

[30]  A. Dutt,et al.  Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian Ethnicity , 2013, PloS one.

[31]  A. Majid,et al.  Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. , 2013, Lung cancer.

[32]  Qing-qing Jiang,et al.  Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients , 2013, Experimental lung research.

[33]  J. Ficker,et al.  EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice , 2013, British Journal of Cancer.

[34]  Y. Bensouda,et al.  Frequency and Type of Epidermal Growth Factor Receptor Mutations in Moroccan Patients with Lung Adenocarcinoma , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[35]  C. Langer,et al.  Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist? , 2013, Lung cancer.

[36]  A. Warth,et al.  EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype , 2013, European Respiratory Journal.

[37]  P. Liu,et al.  Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-small-cell lung cancer , 2013, Virchows Archiv.

[38]  S. Gupta,et al.  Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study , 2013, Journal of carcinogenesis.

[39]  Robert Brian Jenkins,et al.  Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[40]  S. Dacic.  Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations , 2013, Journal of Clinical Pathology.

[41]  C. Liam,et al.  Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma in Malaysian Patients , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[42]  M. Jin,et al.  Evaluation of ALK Rearrangement in Chinese Non-Small Cell Lung Cancer Using FISH, Immunohistochemistry, and Real-Time Quantitative RT- PCR on Paraffin-Embedded Tissues , 2013, PloS one.

[43]  J. Ahn,et al.  Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer , 2013, PloS one.

[44]  S. Ren,et al.  Impact of family history of cancer on the incidence of mutation in epidermal growth factor receptor gene in non-small cell lung cancer patients. , 2013, Lung cancer.

[45]  Gregory Riely,et al.  The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma , 2013, Yonsei medical journal.

[46]  F. Galateau-Sallé,et al.  Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. , 2013, Mutagenesis.

[47]  P. He,et al.  Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  A. Dutt,et al.  EGFR Mutations in Indian Lung Cancer Patients: Clinical Correlation and Outcome to EGFR Targeted Therapy , 2013, PloS one.

[49]  B. Parasuraman,et al.  EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital , 2013, PloS one.

[50]  Suzanne E Dahlberg,et al.  Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[51]  C. Kang,et al.  The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[52]  E. Felip,et al.  Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients , 2013, PloS one.

[53]  Y. Li,et al.  Clinical Significance of EML4-ALK Fusion Gene and Association with EGFR and KRAS Gene Mutations in 208 Chinese Patients with Non-Small Cell Lung Cancer , 2013, PloS one.

[54]  K. Fukuchi,et al.  Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy. , 2012, Lung cancer.

[55]  J. Soh,et al.  Impact of age on epidermal growth factor receptor mutation in lung cancer. , 2012, Lung cancer.

[56]  M. Ladanyi,et al.  Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[57]  K. Nishio,et al.  Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  S. Natsugoe,et al.  EGFR mutations and human papillomavirus in lung cancer. , 2012, Lung cancer.

[59]  J. Pignon,et al.  Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project—Part 2) , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[60]  Li Xiaomei,et al.  Detection of EML4‐ALK fusion genes in non‐small cell lung cancer patients with clinical features associated with EGFR mutations , 2012, Genes, chromosomes & cancer.

[61]  Ronglai Shen,et al.  Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers , 2012, Clinical Cancer Research.

[62]  Shuhang Wang,et al.  EML4-ALK Rearrangement and Its Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer , 2012, Oncology.

[63]  K. Matsuo,et al.  Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. , 2012, Lung cancer.

[64]  Júlio Oliveira,et al.  EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study , 2012, Tumor Biology.

[65]  T. Mok,et al.  Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status , 2012, PloS one.

[66]  W. Lam,et al.  Mitochondrial DNA mutations in respiratory complex‐I in never‐smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation , 2012, Journal of cellular physiology.

[67]  J. Mao,et al.  Development of a rapid and practical mutation screening assay for human lung adenocarcinoma. , 2012, International journal of oncology.

[68]  C. Lee,et al.  Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. , 2012, Lung cancer.

[69]  Sébastien Couraud,et al.  Lung cancer in never smokers--a review. , 2012, European journal of cancer.

[70]  Lan-Jun Zhang,et al.  Relationship between epidermal growth factor receptor gene mutation and copy number in Chinese patients with non-small cell lung cancer , 2012, Chinese journal of cancer.

[71]  E. Ojopi,et al.  Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients , 2012, Clinics.

[72]  M. Ligtenberg,et al.  EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma , 2012, Cellular Oncology.

[73]  Jeffrey W. Clark,et al.  ROS1 rearrangements define a unique molecular class of lung cancers. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[75]  S. Ha,et al.  Distinct clinical features and outcomes in never‐smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement , 2012, Cancer.

[76]  H. Lee,et al.  High Incidence of EGFR Mutations in Korean Men Smokers with No Intratumoral Heterogeneity of Lung Adenocarcinomas: Correlation with Histologic Subtypes, EGFR/TTF-1 Expressions, and Clinical Features , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[77]  M. Olivier,et al.  Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort , 2012, European Respiratory Journal.

[78]  A. Yoshizawa,et al.  Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer. , 2011, Anticancer research.

[79]  R. Rosell,et al.  Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin America , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[80]  I. Takeyoshi,et al.  Clinicopathological features of lung adenocarcinoma with KRAS mutations , 2011, Cancer.

[81]  R. Rao,et al.  Screening for EGFR mutations in lung cancer, a report from India. , 2011, Lung cancer.

[82]  William Pao,et al.  Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma , 2011, European Respiratory Journal.

[83]  Y. Yatabe,et al.  Lung cancers unrelated to smoking: characterized by single oncogene addiction? , 2011, International Journal of Clinical Oncology.

[84]  H. Ji,et al.  Comprehensive Analysis of Epidermal Growth Factor Receptor Gene Status in Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[85]  M. Ladanyi,et al.  Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  M. Ladanyi,et al.  Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  Yeun-Chung Chang,et al.  Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations. , 2011, Lung cancer.

[88]  L. Kleinberg,et al.  EGFR Gene Alterations in a Norwegian Cohort of Lung Cancer Patients Selected for Surgery , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[89]  T. Mitsudomi,et al.  Lung cancer in never smokers: change of a mindset in the molecular era. , 2011, Lung cancer.

[90]  T. Motoyama,et al.  Inverse correlation between EGFR mutation and FHIT, RASSF1A and RUNX3 methylation in lung adenocarcinoma: relation with smoking status. , 2011, Anticancer research.

[91]  L. Crinò,et al.  Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[92]  G. Bepler,et al.  Frequency and Type of Epidermal Growth Factor Receptor Mutations in African Americans with Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[93]  Y. Maehara,et al.  CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non‐small cell lung cancer , 2011, International journal of cancer.

[94]  L. Seymour,et al.  Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[95]  H. Kang,et al.  Association Between Age at Diagnosis and the Presence of EGFR Mutations in Female Patients with Resected Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[96]  R. Bertorelle,et al.  Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. , 2010, Anticancer research.

[97]  H. Jeon,et al.  Somatic Mutations in Epidermal Growth Factor Receptor Signaling Pathway Genes in Non-small Cell Lung Cancers , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[98]  H. Ji,et al.  Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  Wolfgang Viechtbauer,et al.  Conducting Meta-Analyses in R with the metafor Package , 2010 .

[100]  H. Ji,et al.  Spectrum of LKB1, EGFR, and KRAS Mutations in Chinese Lung Adenocarcinomas , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[101]  H. Uramoto,et al.  Correlation Between HLA Alleles and EGFR Mutation in Japanese Patients with Adenocarcinoma of the Lung , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[102]  E. Imyanitov,et al.  High Efficacy of First-Line Gefitinib in Non-Asian Patients with EGFR-Mutated Lung Adenocarcinoma , 2010, Oncology Research and Treatment.

[103]  A. Yoshizawa,et al.  Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene , 2010, Annals of Surgical Oncology.

[104]  Hoguen Kim,et al.  Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer , 2010, Journal of Cancer Research and Clinical Oncology.

[105]  A. Gemma,et al.  Frequency of and variables associated with the EGFR mutation and its subtypes , 2010, International journal of cancer.

[106]  S. Dacic,et al.  Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas , 2010, Modern Pathology.

[107]  J. Subramanian,et al.  Lung cancer in 'Never-smokers': a unique entity. , 2010, Oncology.

[108]  D. Jackman,et al.  Fire without smoke: lung cancer in 'never-smokers'. , 2010, Oncology.

[109]  Mariano Provencio,et al.  Screening for epidermal growth factor receptor mutations in lung cancer. , 2009, The New England journal of medicine.

[110]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[111]  Paul N. Smith,et al.  The status of KRAS mutations in patients with non-small cell lung cancers from mainland China. , 2009, Oncology reports.

[112]  C. Tibaldi,et al.  Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study. , 2009, Oncology reports.

[113]  J. Soh,et al.  Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer. , 2009, Lung cancer.

[114]  N. Wada,et al.  Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. , 2009, Lung cancer.

[115]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[116]  Hoguen Kim,et al.  Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma , 2009, Journal of Cancer Research and Clinical Oncology.

[117]  L. Mao,et al.  Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  A. Paradiso,et al.  EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib , 2009, Journal of Cancer Research and Clinical Oncology.

[119]  E. Wardelmann,et al.  Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling , 2009, Journal of Cancer Research and Clinical Oncology.

[120]  A. Sihoe,et al.  The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS , 2009, Cancer.

[121]  Hee Kyung Chang,et al.  EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung , 2009, The Korean Journal of Internal Medicine.

[122]  Y. Ishikawa,et al.  EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset , 2009, Modern Pathology.

[123]  Y. Ishikawa,et al.  Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type. , 2009, Lung cancer.

[124]  E. Campo,et al.  EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. , 2009, The American journal of pathology.

[125]  Takayuki Kosaka,et al.  Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[126]  H. Koong,et al.  Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-small Cell Lung Cancer (NSCLC) , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[127]  Shiu-Feng Huang,et al.  Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications , 2008, Cancer.

[128]  E. C. Xu,et al.  Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients. , 2008, Lung cancer.

[129]  Christoph Plass,et al.  Lung cancer epigenetics and genetics , 2008, International journal of cancer.

[130]  J. Subramanian,et al.  Molecular genetics of lung cancer in people who have never smoked. , 2008, The Lancet. Oncology.

[131]  Derek Y. Chiang,et al.  EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.

[132]  G A Colditz,et al.  Comparison of aspects of smoking among the four histological types of lung cancer , 2008, Tobacco Control.

[133]  E. Stathopoulos,et al.  ‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer , 2007, British Journal of Cancer.

[134]  J. Soh,et al.  The Impact of Sex and Smoking Status on the Mutational Spectrum of Epidermal Growth Factor Receptor Gene in Non–small Cell Lung Cancer , 2007, Clinical Cancer Research.

[135]  Teruhiko Yoshida,et al.  Epidermal Growth Factor Receptor Mutation Detection Using High-Resolution Melting Analysis Predicts Outcomes in Patients with Advanced Non–Small Cell Lung Cancer Treated with Gefitinib , 2007, Clinical Cancer Research.

[136]  Tomoki Yokoyama,et al.  Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler. , 2007, Oncology reports.

[137]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[138]  Y. Miyagi,et al.  Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. , 2007, American journal of clinical pathology.

[139]  Yunjung Choi,et al.  The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression. , 2007, Lung cancer.

[140]  Y. Bang,et al.  ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. , 2007, Lung cancer.

[141]  P. Hainaut,et al.  Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. , 2007, Cancer research.

[142]  T. Mok,et al.  Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[143]  Y. Yatabe,et al.  Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib , 2007, British Journal of Cancer.

[144]  Janakiraman Subramanian,et al.  Lung cancer in never smokers: a review. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  K. Matsuo,et al.  Risk factors differ for non‐small‐cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case‐control study in Japanese , 2007, Cancer science.

[146]  P. Laurent-Puig,et al.  Epidermal Growth Factor Receptor Mutation in Lung Cancer are Linked to Bronchioloalveolar Differentiation , 2006, The American journal of surgical pathology.

[147]  J. Siegfried,et al.  Mutation and Polymorphism in the EGFR-TK Domain Associated with Lung Cancer , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[148]  H. Osada,et al.  EGFR point mutation in non‐small cell lung cancer is occasionally accompanied by a second mutation or amplification , 2006, Cancer science.

[149]  M. Maemondo,et al.  Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[150]  J. Minna,et al.  Exclusive mutation in epidermal growth factor receptor gene, HER‐2, and KRAS, and synchronous methylation of nonsmall cell lung cancer , 2006, Cancer.

[151]  M. Borenstein,et al.  Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments , 2006 .

[152]  G. Fountzilas,et al.  Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients. , 2006, Lung cancer.

[153]  R. Wilson,et al.  Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[154]  T. Oyama,et al.  Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking , 2006, British Journal of Cancer.

[155]  J. Minna,et al.  Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features , 2006, Clinical Cancer Research.

[156]  M. Spitz,et al.  Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[157]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[158]  Yih-Leong Chang,et al.  Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer , 2006, International journal of cancer.

[159]  H. Sasaki,et al.  A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. , 2006, Japanese journal of clinical oncology.

[160]  S. Toyooka,et al.  Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. , 2006, Cancer research.

[161]  J. Minna,et al.  Clinicopathologic Significance of the Mutations of the Epidermal Growth Factor Receptor Gene in Patients with Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[162]  Mayumi Ono,et al.  Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas , 2005, Clinical Cancer Research.

[163]  L. Zhang,et al.  The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[164]  C. García-Girón,et al.  Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[165]  C. Tzen,et al.  Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. , 2005, Chest.

[166]  P. Hainaut,et al.  TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. , 2005, Cancer research.

[167]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[168]  Young Tae Kim,et al.  Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[169]  W. Park,et al.  Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas , 2005, Virchows Archiv.

[170]  Leah E. Mechanic,et al.  Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[171]  Xiao Chen,et al.  Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy , 2005, Cell Research.

[172]  S. Toyooka,et al.  The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[173]  A. Marchetti,et al.  EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[174]  Joachim Herz,et al.  Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? , 2004, Trends in molecular medicine.

[175]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[176]  F. Gilliland,et al.  Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression. , 2003, Cancer research.

[177]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[178]  D. Sidransky,et al.  Cigarette smoking is strongly associated with mutation of the K‐ras gene in patients with primary adenocarcinoma of the lung , 2001, Cancer.

[179]  L. Hedges,et al.  The power of statistical tests in meta-analysis. , 2001, Psychological methods.

[180]  C. Harris,et al.  p53 and K-ras mutations in lung cancers from former and never-smoking women. , 2001, Cancer research.

[181]  Y. Yamashita,et al.  K-ras gene mutations in non-small cell lung cancer in Japanese. , 2000, Oncology reports.

[182]  E. Mark,et al.  Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. , 1999, Journal of the National Cancer Institute.

[183]  M. Higashiyama,et al.  A novel molecular staging protocol for non-small cell lung cancer , 1999, Oncogene.

[184]  J. Luketich,et al.  Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[185]  A. Marchetti,et al.  Genetic analysis of lung tumours of non-smoking subjects: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus. , 1998, British Journal of Cancer.

[186]  U. Pastorino,et al.  Prognostic value of loss of heterozygosity and KRAS2 mutations in lung adenocarcinoma , 1998, International journal of cancer.

[187]  J. Siegfried,et al.  Detection of K-ras mutations in lung carcinomas: relationship to prognosis. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[188]  M. Ridanpää,et al.  K‐ras mutations in human adenocarcinoma of the lung: Association with smoking and occupational exposure to asbestos , 1993, International journal of cancer.

[189]  M. Lung,et al.  Incidence of ras oncogene activation in lung carcinomas in Hong Kong , 1992, Cancer.

[190]  K. Sugimachi,et al.  ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. , 1992, Cancer research.

[191]  S. Rodenhuis,et al.  Clinical significance of ras oncogene activation in human lung cancer. , 1992, Cancer research.

[192]  S. Rodenhuis,et al.  Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. , 1991, Journal of the National Cancer Institute.

[193]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[194]  E. Naseva,et al.  EGFR mutations in patients with non small-cell lung cancer in Bulgaria and treatment with gefitinib. , 2015, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[195]  S. Conde,et al.  Estudo da mutação do recetor do fator de crescimento epidérmico, durante 5 anos, numa população de doentes com cancro do pulmão de não pequenas células , 2013 .

[196]  Satoru Miyano,et al.  Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. , 2012, Cancer research.

[197]  Neringa Vagulienė,et al.  The role of mutation status of the epidermal growth factor receptor gene in advanced non-small cell lung cancer. , 2012, Medicina.

[198]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[199]  Young Yang,et al.  Open Access RESEARCH , 2010 .

[200]  Alona Muzikansky,et al.  Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. , 2007, The oncologist.

[201]  Chih-Yi Chen,et al.  Analysis of K-ras gene mutations in lung carcinomas: correlation with gender, histological subtypes, and clinical outcome , 1998, Journal of Cancer Research and Clinical Oncology.

[202]  C. Rudin,et al.  Lung cancer in 'never-smokers': beyond EGFR mutations and EGFR-TK inhibitors. , 1970 .